Royalty Pharma

Royalty Pharma acquires passive royalty interests in already-approved or late-stage drugs, meaning it receives a top-line royalty payment on sales but has no operational involvement in drug development. This contrasts with a biotech fund that typically takes equity stakes in developers and bears the binary risk of clinical-trial outcomes. By owning royalties across more than 35 commercial products, Royalty Pharma generates cash flows from diversified therapeutic areas without the risk profile of a single-asset biotech investment.

Pablo Legorreta, as founder and CEO, leads the investment committee. The senior deal team includes Chief Investment Officer Marshall Urist and other senior managing directors who evaluate potential royalty transactions. The firm's structure as a permanent-capital public company means investment decisions are made entirely by the internal team without external limited-partner advisory boards.

The firm's primary instrument is pure royalty acquisitions, but it has increasingly used synthetic royalty structures and revenue-linked bonds that provide non-dilutive funding to biotech companies in exchange for a percentage of future drug sales. It typically does not take equity, although some synthetic deals include warrants or capped returns. The core thesis remains focused on passive, non-voting revenue participation rather than active operating control.

Royalty Pharma sources deals primarily through direct outreach to academic institutions, research hospitals, and inventor estates holding royalty entitlements on approved drugs. Legorreta's decades-long network within pharmaceutical licensing and the firm's public stature make it the first call for many sellers seeking liquidity. The firm does not rely on competitive auction processes for the majority of its transactions, giving it a sourcing advantage over occasional entrants into the royalty space.

Yes, Royalty Pharma maintains the Royalty Pharma Charitable Foundation, which directs grants toward global health, education, and scientific research. The foundation is funded by the firm's corporate profits and operates as a separate legal entity focused on equitable access to healthcare innovation, with disclosure of its grant-making published annually in the firm's ESG reports.

Because Royalty Pharma acquires contractual payment rights, not drug marketing authorizations, its transactions do not require regulatory approval from agencies like the FDA. The firm is subject to SEC reporting as a Nasdaq-listed company and faces the same disclosure and governance requirements as any publicly traded corporation, including quarterly financial reporting and audited statements.

Royalty Pharma is a self-capitalized public entity, not a fund manager. It does not raise commit-and-draw-down capital from limited partners with a 7-to-10-year fund life. Instead, its balance sheet is the investment vehicle—funded by public equity and debt—meaning there is no redemption pressure or forced divestiture timeline. This permanent capital lets it hold royalty assets for the full term of a drug's patent life, aligning with the long-duration nature of pharmaceutical cash flows.